On July 10, WuXi XDC rose 3.37% in regular trading, trading at HK$61.45/share, with turnover of approximately HK$53.51 million.

On the news front, multiple international investment banks recently issued positive research reports. CLSA raised its target price for WuXi XDC from HK$80.9 to HK$82.6, maintaining an Outperform rating, forecasting strong growth in new project acquisitions in the first half, continued expansion of global ADC outsourcing market share, and revenue plus adjusted net profit growth exceeding guidance. CLSA projects revenue growth of 33%, 31%, and 28% for the next three years, with net profit growth of 11%, 51%, and 33% respectively. Separately, Daiwa initiated coverage with a Buy rating and HK$78 target price, designating the company as a top pick in the China CXO sector, citing its 24% ADC market share and full-chain CRDMO service capabilities.

Within the Life Sciences Tools and Services sector, broad sector strength was evident, with Pharmaron up 7.12%, WuXi Biologics up 5.61%, and WuXi AppTec up 5.44%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)